Skip to main content
Home

Breadcrumb

  1. Home
  2. Consultancy

Consultancy

Smiling woman next to text reading "Solving people and performance challenges with human-centred design, learning and communication. Challenges like… Adopting AI." Promoting Acteon's refreshed website.
28 April 2026

Acteon's new-look website speaks to common challenges in the world of work

From AI adoption to L&D that drives business results, Acteon's refreshed site shows how a behavioural, human-centred approach can turn today's toughest challenges into real change. ...

rom dispersed inputs to integrated outcomes: where decision confidence is formed may matter more than where deals are signed.
28 April 2026

From licensing to integration: is decision-making in life sciences moving upstream?

Recent cross-border licensing activity involving China-origin biopharmaceutical assets suggests a subtle but important shift in how global partnerships are being structured. While attention often focuses on total deal value, the more meaningful signal may lie in the underlying terms. ...

Drawing of the Spice Girls if they worked in corporate.
6 May 2026

AI adoption isn't a tech challenge - it's a behaviour change challenge

Acteon's Rebecca Trigg uses a playful framework inspired by the Spice Girls to explore the different responses to AI adoption in organisations – and explains why understanding people, not technology, is the key to lasting change. ...

23 August 2026

ERA 2026 Update (WEBINAR) - 26 May 2026

Things have changed in employment law. And most small businesses have not caught up yet.If you are employing people, you cannot afford to be guessing what applies to you and what does not.We are running a free, practical webinar where our HR experts will walk through:what has already ch...

ai image
21 April 2026

When both sides have rules: What this means for UK–China life sciences collaboration

For UK life sciences businesses engaging with China, the operating environment has become more structured than many still assume. Not because the opportunity has diminished — it has not — but because the conditions for realising it now require a different level of preparation. Understan...

PEM Corporate Finance Team, three business men in a garden in Cambridge
21 April 2026

PEM advises Prestige Purchasing Holdings Ltd on its acquisition by Entegra Europe UK Ltd.

PEM has advised Prestige Purchasing Holdings Limited on its acquisition by Entegra Europe UK Limited, a subsidiary of Sodexo S.A., in a transaction that strengthens Entegra’s position in the UK hospitality and procurement sector.The transaction sees Entegra Europe UK acquire 100% of Pre...

Anthias attends 3 conferences this Spring
22 April 2026

Anthias Consulting attends a number of conferences in Spring 2026

With a busy few months ahead with our training and consultancy calendar, the Anthias team are taking time out to head to a few well known conferences over the next couple of months to present talks, network with members of the industry and gather insight into all the latest trends. ...

Medical device manufacturing scale-up in Cambridge
20 April 2026

Bridging Cambridge’s MedTech scale-up gap: the missing link between prototype and production

Cambridge leads in early-stage MedTech innovation, but many promising ideas stall when moving from lab prototypes to clinical-ready devices. The core challenge lies in fragmented, early-stage manufacturing and regulatory pathways, often pushing companies to look overseas. This reflects ...

Speak to the Human podcast
17 April 2026

Speak to the Human returns with a new host, and a first episode that tackles one of the biggest challenges facing organisations and leaders right now: AI adoption.

Speak to the Human returns with a new host, James Woodman. Building on the first 23 episodes hosted by Sarah Abramson, the podcast explores how people think, behave, and make decisions at work. Through real stories and practical conversations, each episode investigates the hum...

Ophthalmic drug delivery
16 April 2026

The retinal delivery bottleneck: why today’s tools won’t scale

Cell and gene therapies make up a large and growing proportion of pipeline treatments for high-prevalence diseases of the retina. For these advanced therapies to deliver on their promise, most need to be delivered into the retina, overcoming significant physiological barriers. But exist...

Pagination

  • First page «
  • Previous page ‹‹
  • …
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • …
  • Next page ››
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS